<DOC>
	<DOC>NCT02345408</DOC>
	<brief_summary>This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.</brief_summary>
	<brief_title>Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologically or cytologically confirmed nonresectable pancreatic adenocarcinoma with or without metastases Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 Anticipated life expectancy ≥ 12 weeks Radiographically measurable disease acc. to RECIST 1.1 Use of adequate contraception (as described in protocol) Ability to provide written informed consent and comply with study requirements Received other cancer treatment or investigational drug within 4 weeks prior to screening Women who are pregnant or breastfeeding Had major surgery within 4 weeks of first dose of study drug Inadequate liver, renal or bone marrow function within 2 weeks of first dose Serious concurrent illness, altered medical status or any uncontrolled medical condition Any infection requiring antibiotic or antiviral treatment within 4 weeks of screening Known active HIV, HBV or HCV infection Inability to swallow tablets History or presence of any medical condition or disease which, in the opinion of the investigator, may place the subject at unacceptable risk for study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>